iHealth-T2D研究:针对中心性肥胖和糖尿病前期的南亚人群预防2型糖尿病的随机对照试验研究方案
该研究为在印度、巴基斯坦、斯里兰卡和英国开展的整群随机对照试验,共120个站点,目标招募3600名40-70岁中心性肥胖和/或糖尿病前期的南亚裔成年人,1:1分配至社区健康工作者实施的12个月生活方式干预组或常规护理组,随访3年,主要终点为新发2型糖尿病。研究已筛查33212人,3682人同意参与,截至2019年底观察到的2型糖尿病年发病率为6.1%。
要点
- 在四个国家120个站点开展整群随机对照试验,比较社区健康工作者主导的12个月生活方式干预与常规护理。
- 纳入标准为40-70岁南亚裔,伴有中心性肥胖和/或糖化血红蛋白6.0-6.4%的糖尿病前期。
- 主要终点为3年时新发2型糖尿病,定义为糖化血红蛋白≥6.5%或医生诊断并接受治疗。
核心结论
- iHealth-T2D研究将增进对南亚人群糖尿病预防策略的理解,采用适合低资源环境的筛查和干预方法。
- 研究结果将为改善这一全球主要族群健康与福祉的策略实施提供信息。
研究设计与样本
- 整群随机临床试验,1:1分配至干预或常规护理,在印度、巴基斯坦、斯里兰卡和英国开展,每国30个站点,共120个站点。
- 目标招募3600人(每站点30人),每年随访,持续3年。
- 纳入标准:南亚裔男性或女性,年龄40-70岁,伴有中心性肥胖(印度和巴基斯坦腰围≥100 cm;斯里兰卡≥90 cm)和/或糖尿病前期(糖化血红蛋白6.0-6.4%含界值)。
- 排除标准:已知1型或2型糖尿病、体重正常或偏瘦(体重指数<22 kg/m²)、妊娠或计划妊娠、居住不稳定或计划离开该地区、严重疾病。
- 已筛查33212人,10930人符合入选标准,3682人同意参与;参与者49.2%为女性,年龄52.8(标准差8.2)岁。
主要发现
- 干预组和常规护理站点的临床特征均衡。
- 超过90%的随访访视计划于2020年12月完成。
- 基于截至2019年底的随访,研究人群中观察到的2型糖尿病发病率与预期一致(每年6.1%)。
关键数值与推荐
- 主要终点为3年时新发2型糖尿病,定义为糖化血红蛋白≥6.5%或医生诊断并接受2型糖尿病治疗。
- 1年和3年的次要终点包括:体格测量(腰围、体重和血压);生活方式指标(吸烟状况、酒精摄入、体力活动和膳食摄入);生化指标(空腹血糖、胰岛素和血脂,包括总胆固醇和高密度脂蛋白胆固醇、甘油三酯);以及治疗依从性。
- 生活方式干预由经过培训的社区健康工作者在12个月内实施,包括5次一对一课程、4次小组课程和13次电话课程,目标是参与者通过改善饮食和增加体力活动使体重指数降低7%、腰围减少10 cm。
- 常规护理包括由社区健康工作者提供的一次30分钟的生活方式调整建议。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People from South Asia are at increased risk of type 2 diabetes (T2D). There is an urgent need to develop approaches for the prevention of T2D in South Asians that are cost-effective, generalisable and scalable across settings. HYPOTHESIS: Compared to usual care, the risk of T2D can be reduced amongst South Asians with central obesity or raised HbA1c, through a 12-month lifestyle modification programme delivered by community health workers. DESIGN: Cluster randomised clinical trial (1:1 allocation to intervention or usual care), carried out in India, Pakistan, Sri Lanka and the UK, with 30 sites per country (120 sites total). Target recruitment 3600 (30 participants per site) with annual follow-up for 3 years. ENTRY CRITERIA: South Asian, men or women, age 40-70 years with (i) central obesity (waist circumference ≥ 100 cm in India and Pakistan; ≥90 cm in Sri Lanka) and/or (ii) prediabetes (HbA1c 6.0-6.4% inclusive). EXCLUSION CRITERIA: known type 1 or 2 diabetes, normal or underweight (body mass index < 22 kg/m2); pregnant or planning pregnancy; unstable residence or planning to leave the area; and serious illness. ENDPOINTS: The primary endpoint is new-onset T2D at 3 years, defined as (i) HbA1c ≥ 6.5% or (ii) physician diagnosis and on treatment for T2D. Secondary endpoints at 1 and 3 years are the following: (i) physical measures: waist circumference, weight and blood pressure; (ii) lifestyle measures: smoking status, alcohol intake, physical activity and dietary intake; (iii) biochemical measures: fasting glucose, insulin and lipids (total and HDL cholesterol, triglycerides); and (iv) treatment compliance. INTERVENTION: Lifestyle intervention (60 sites) or usual care (60 sites). Lifestyle intervention was delivered by a trained community health worker over 12 months (5 one-one sessions, 4 group sessions, 13 telephone sessions) with the goal of the participants achieving a 7% reduction in body mass index and a 10-cm reduction in waist circumference through (i) improved diet and (ii) increased physical activity. Usual care comprised a single 30-min session of lifestyle modification advice from the community health worker. RESULTS: We screened 33,212 people for inclusion into the study. We identified 10,930 people who met study entry criteria, amongst whom 3682 agreed to take part in the intervention. Study participants are 49.2% female and aged 52.8 (SD 8.2) years. Clinical characteristics are well balanced between intervention and usual care sites. More than 90% of follow-up visits are scheduled to be complete in December 2020. Based on the follow-up to end 2019, the observed incidence of T2D in the study population is in line with expectations (6.1% per annum). CONCLUSION: The iHealth-T2D study will advance understanding of strategies for the prevention of diabetes amongst South Asians, use approaches for screening and intervention that are adapted for low-resource settings. Our study will thus inform the implementation of strategies for improving the health and well-being of this major global ethnic group. IRB APPROVAL: 16/WM/0171 TRIAL REGISTRATION: EudraCT 2016-001350-18 . Registered on 14 April 2016. ClinicalTrials.gov NCT02949739 . Registered on 31 October 2016, First posted on 31/10/2016.
引用
- Kasturiratne A, Khawaja KI, Ahmad S, et al. The iHealth-T2D study, prevention of type 2 diabetes amongst South Asians with central obesity and prediabetes: study protocol for a randomised controlled trial. Trials. 2021. PMID: 34922608. doi:10.1186/s13063-021-05803-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。